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Case Report

Urinary bladder metastasis from breast cancer: a rare
cause of hematuria
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Abstract
Breast cancer is the most common cancer in women globally as well as in Kenya. The most common sites of metastases
reported include the bones, liver and lung. Metastasis to the urinary bladder is relatively uncommon with only a few
case reports in literature. It can therefore be easily overlooked as a cause of hematuria in these patients. We describe
a rare case of a patient with breast cancer who presented with urinary bladder metastasis as a late complication of her
illness.

Case review
A 54-year-old female presented with 1 week history of
self-discovered left breast lump in August 2010. The lump
was painless with no skin or nipple changes and no axillary swelling. She was post-menopausal with three grown
children. She was a lifelong non-smoker and did not take
alcohol. There was no family history of cancer. Initial
mammography and left breast ultrasound revealed a 1.4
× 0.9 cm irregular mass in the left upper outer quadrant.
Biopsy of the lesion confirmed invasive lobular carcinoma
that was estrogen receptor (ER) and progesterone receptor
(PR) positive and human epidermal growth factor-2
(HER2) equivocal (2+), for which, HER2 Fluorescence
in situ hybridization was negative. Bone scan showed
two areas of increased uptake in the proximal and distal
portion of the sternum suggestive of metastases. She had
no other sites of metastases. In view of the oligometastatic
disease, the patient was treated aggressively with modified
radical mastectomy followed by adjuvant chemotherapy
and radiotherapy. She was then started on endocrine
therapy.
4 years later, she presented with increased bone pain which
on CT scan and bone scan confirmed extensive bone
metastases but no other sites of disease. She received palliative radiotherapy to the spine and treatment changed to
everolimus and fulvestrant with denosumab. In 2016, she
had skin nodules which were confirmed on biopsy to be
invasive lobular carcinoma (ER/PR positive and HER2
negative). Therapy changed to single agent capecitabine.

7 years after her initial diagnosis, the patient presented with
abdominal fullness and hematuria. CT scan now showed
extensive bladder wall thickening (Figure 1), new onset
ascites and pleural effusion. Cystoscopy confirmed multiple
tumor deposits in the bladder. Unfortunately, no sample
was submitted for histology. Bilateral ureteric stents were
inserted, ascitic and pleural drains inserted and patient
regimen was changed. Her ECOG performance status
remained one and received further lines of chemotherapy
including gemcitabine and carboplatin, eribulin and nab-
paclitaxel. 9 months after diagnosis of bladder metastases,
her condition deteriorated and she was transitioned to
best supportive care and she eventually succumbed to her
illness.
Discussion
While breast cancer is the most common malignancy in
females, metastases to the urinary bladder are extremely
rare. Approximately, 54 cases have been reported in literature to date.1 In several autopsy studies, the rate of bladder
metastases from breast cancer range from 1.2 to 7%.1
Bladder metastases more commonly arise from tumors in
the pelvic region such as the cervix, rectum and prostate.2
Breast cancer more commonly spreads to the liver, lung and
bone.2,3
As in our patient, the most common histological subtype
associated with bladder metastases is invasive lobular carcinoma even though invasive ductal carcinoma is the most
common histological subtype of primary breast cancer.1,2,4
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Figure 1. A 54-year-old female with breast cancer presenting
with hematuria. Axial (a) and sagittal (b) CT images of the of
the pelvis show enhancing irregular bladder wall thickening
(arrows).

The postulated mechanisms of spread from the breast primary
to the bladder include hematogenous spread of viable tumor
emboli through pulmonary circulation without establishing lung
metastases with subsequent bladder involvement. It is postulated
that because invasive lobular carcinoma loses e-cadherin, this
leads to more metastases as cell–cell adhesion is lost. In addition,
lobular carcinoma being a serosal type cancer is likely to spread
into the gastrointestinal system and genitourinary system.2
The most common presentation of patients with bladder metastases as with our case is gross hematuria. Other signs and symptoms include urinary frequency, incontinence, dysuria, lower
abdominal pain and back pain.5–7 There is a recent report of
an asymptomatic patient found to have bladder metastases on
routine follow up CT scan 2 years after initial therapy for breast
cancer.8

Imaging for patients suspected to have bladder metastases include
bladder ultrasound, CT scan or MRI of the pelvis. Typically,
bladder wall thickening is seen with or without hydronephrosis
and hydroureter. Cystoscopy is mandatory for confirming the
diagnosis. In majority of the case reports, cystoscopy revealed
large tumor deposits as was found in our patient described
above.9 Histology and immunohistochemistry including
staining for ER and PR as well as HER2 is crucial in confirming
the primary tumor from breast and to exclude a primary bladder
cancer. Discordance in hormonal status in primary and metastatic sites has however been reported to be around 24 and 39%.1
More recent publications have not found additional information
to that reported in previously cited literature.3,4
Therapies include local resection of the bladder tumor during
cystoscopy, palliative radiotherapy and systemic therapy. Ureteric
stenting may also be indicated for those with hydronephrosis and
renal dysfunction. It has been reported that survival is short after
diagnosis of bladder metastases.10
Conclusion
Metastases to urinary bladder from breast cancer is a rare
occurrence but should be considered for breast cancer patients
presenting with urinary symptoms, in particular hematuria.
Leaning points
1. Although rare, urinary bladder metastasis from breast
cancer should be considered for patients presenting with
urinary symptoms, in particular hematuria.
2. The most common histological subtype associated with
bladder metastases is invasive lobular carcinoma.
3. Cystoscopy is recommended for patients with invasive
lobular carcinoma presenting with hematuria to exclude
bladder metastasis.
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